Brainstorm and Loulou Foundation provided funding for rare genetic epilepsy initiatives and adopted FDA-encouraged methodologies.
1 report, 1 independent
Updated May 28
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Brainstorm and Loulou Foundation provided funding for rare genetic epilepsy initiatives and adopted FDA-encouraged methodologies.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- The FDA approved FINTEPLA for the treatment of rare epilepsy.Sub-event
Brainstorm funds rare genetic epilepsy research and adopts new FDA-encouraged methodologies.1 source
Keep exploring
The entities involved
-
Brainstorm
company in Madrid, Spain
Nothing else this week.
- FDA
Related events
- Neurogene Inc. developed a gene therapy for Rett syndrome and received FDA agreement for a registrational trial design.
- FDA is willing to review updated submissions, while biotech hubs leverage AI to ease clinical development bottlenecks.
- A network focused on cell and gene therapies is expanding to include sites in Northern California, involving the CA Institute for Regenerative Medicine and the FDA.